Business Description
Novartis AG
NAICS : 325412
ISIN : US66987V1098
Share Class Description:
STU:NOTA: ADRDescription
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.44 | |||||
| Equity-to-Asset | 0.42 | |||||
| Debt-to-Equity | 0.74 | |||||
| Debt-to-EBITDA | 1.58 | |||||
| Interest Coverage | 14.37 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 3.7 | |||||
| Beneish M-Score | -2.18 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 4.3 | |||||
| 3-Year EPS without NRI Growth Rate | 4.6 | |||||
| 3-Year FCF Growth Rate | 4.2 | |||||
| 3-Year Book Growth Rate | -3.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 25.52 | |||||
| Future 3-5Y Total Revenue Growth Rate | 5.21 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 20.78 | |||||
| 9-Day RSI | 29.27 | |||||
| 14-Day RSI | 33.11 | |||||
| 6-1 Month Momentum % | 1.44 | |||||
| 12-1 Month Momentum % | 11.26 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.11 | |||||
| Quick Ratio | 0.9 | |||||
| Cash Ratio | 0.5 | |||||
| Days Inventory | 169.69 | |||||
| Days Sales Outstanding | 55.82 | |||||
| Days Payable | 123.57 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 3.68 | |||||
| Dividend Payout Ratio | 0.65 | |||||
| 3-Year Dividend Growth Rate | 3.8 | |||||
| Forward Dividend Yield % | 3.68 | |||||
| 5-Year Yield-on-Cost % | 4 | |||||
| 3-Year Average Share Buyback Ratio | 3.2 | |||||
| Shareholder Yield % | 7.17 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 74.92 | |||||
| Operating Margin % | 27.26 | |||||
| Net Margin % | 35.14 | |||||
| FCF Margin % | 24.98 | |||||
| ROE % | 41.66 | |||||
| ROA % | 17.16 | |||||
| ROIC % | 13.56 | |||||
| ROC (Joel Greenblatt) % | 127 | |||||
| ROCE % | 19.58 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 11.95 | |||||
| Forward PE Ratio | 12.5 | |||||
| PE Ratio without NRI | 17.71 | |||||
| Shiller PE Ratio | 16.85 | |||||
| Price-to-Owner-Earnings | 9.9 | |||||
| PS Ratio | 4.17 | |||||
| PB Ratio | 4.84 | |||||
| Price-to-Free-Cash-Flow | 16.68 | |||||
| Price-to-Operating-Cash-Flow | 13.06 | |||||
| EV-to-EBIT | 16.17 | |||||
| EV-to-Forward-EBIT | 12.21 | |||||
| EV-to-EBITDA | 11.24 | |||||
| EV-to-Forward-EBITDA | 10.18 | |||||
| EV-to-Revenue | 4.43 | |||||
| EV-to-Forward-Revenue | 4.12 | |||||
| EV-to-FCF | 17.8 | |||||
| Price-to-Projected-FCF | 1.31 | |||||
| Price-to-Median-PS-Value | 1.07 | |||||
| Earnings Yield (Greenblatt) % | 6.19 | |||||
| FCF Yield % | 6.12 | |||||
| Forward Rate of Return (Yacktman) % | 10.12 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Novartis AG Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 45,775.052 | ||
| EPS (TTM) (€) | 7.82 | ||
| Beta | 0.39 | ||
| Volatility % | 13.66 | ||
| 14-Day RSI | 33.11 | ||
| 14-Day ATR (€) | 1.123372 | ||
| 20-Day SMA (€) | 97.79 | ||
| 12-1 Month Momentum % | 11.26 | ||
| 52-Week Range (€) | 86.4 - 109 | ||
| Shares Outstanding (Mil) | 1,999.27 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Novartis AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Novartis AG Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Novartis AG Frequently Asked Questions
What is Novartis AG(STU:NOTA)'s stock price today?
The current price of STU:NOTA is €95.40. The 52 week high of STU:NOTA is €109.00 and 52 week low is €86.40.
When is next earnings date of Novartis AG(STU:NOTA)?
The next earnings date of Novartis AG(STU:NOTA) is 2025-01-31.
Does Novartis AG(STU:NOTA) pay dividends? If so, how much?
The Dividend Yield %  of Novartis AG(STU:NOTA) is 3.68% (As of Today), Highest Dividend Payout Ratio of Novartis AG(STU:NOTA) was 1.19. The lowest was 0.33. And the median was 0.85. The  Forward Dividend Yield % of Novartis AG(STU:NOTA) is 3.68%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers